Albumin fusion proteins

• US 7,507,413 B2
• Filed: 09/03/2004
• Issued: 03/24/2009
• Est. Priority Date: 04/12/2001
• Status: Expired due to Term

• Current Assignee: Human Genome Sciences Incorporated (GSK plc)
• Original Assignee: Human Genome Sciences Incorporated (GSK plc)
• Inventors: Rosen, Craig A., Haseltine, William A.
• Primary Examiner(s): ROBINSON, HOPE A
• Application Number:
  US10/933,523
• Publication Number:
  US 20070026013A1
• Time in Patent Office: 1,663 Days
• Field of Search: None
• US Class Current: 424/192.1
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 5/06 of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
• CPC Class Codes: C07K 14/765 Serum albumin, e.g. HSA
• CPC Class Codes: C12N 15/62 DNA sequences coding for fusion proteins

Abstract

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

Claims

1. An albumin fusion protein comprising a fractalkine polypeptide fused to an albumin polypeptide, wherein said fractalkine polypeptide is selected from:

(a) a full-length fractalkine;

(b) a mature fractalkine; and

(c) a fragment of fractalkine, wherein said fragment has chemotactic activity;

and wherein said albumin polypeptide is selected from;

(i) a full-length albumin;

(ii) a mature albumin;

(iii) a fragment of albumin, wherein said fragment of albumin has the ability to prolong the serum half-life of the fused fractalkine polypeptide compared to the unfused fractalkine polypeptide;

(iv) a polypeptide consisting of an amino acid sequence at least 95% identical to albumin (SEQ ID NO;

18), wherein said polypeptide has the ability to prolong the serum half-life of the fused fractalkine polypeptide compared to the unfused fractalkine polypeptide;

(v) amino acids 1 to 585 of SEQ ID NO;

18; and

(vi) amino acids 1 to 387 of SEQ ID NO;

18.

2. The albumin fusion protein of claim 1, wherein said fractalkine polypeptide is mature fractalkine and said albumin polypeptide is full-length albumin.

3. The albumin fusion protein of claim 1, wherein said fractalkine polypeptide is full-length fractalkine and said albumin polypeptide is mature albumin.

4. The albumin fusion protein of claim 1, wherein said fractalkine polypeptide is mature fractalkine and said albumin polypeptide is mature albumin.

5. The albumin fusion protein of claim 1, wherein said fractalkine polypeptide is mature fractalkine and said albumin polypeptide is a fragment of albumin.

6. The albumin fusion protein of claim 1, wherein said fractalkine polypeptide is a fragment of fractalkine and said albumin polypeptide is mature albumin.

7. The albumin fusion protein of claim 1, wherein said fractalkine polypeptide is a fragment of fractalkine and said albumin polypeptide is a fragment of albumin.

8. The albumin fusion protein of claim 1, wherein said albumin polypeptide is at least 99% identical to albumin (SEQ ID NO:

18).

9. The albumin fusion protein of claim 1, wherein said fractalkine polypeptide is fused to the N-terminus of the albumin polypeptide.

10. The albumin fusion protein of claim 1, wherein said fractalkine polypeptide is fused to the C-terminus of the albumin polypeptide.

11. The albumin fusion protein of claim 1, wherein said fractalkine polypeptide is fused to the N-terminus and C-terminus of the albumin polypeptide.

12. The albumin fusion protein of claim 1, further comprising a secretion leader sequence.

13. The albumin fusion protein of claim 1, which is non-glycosylated.

14. The albumin fusion protein of claim 1, which is expressed in yeast.

15. The albumin fusion protein of claim 14, wherein said yeast is a Saccharomyces cerevisiae.

16. The albumin fusion protein of claim 14, wherein said yeast is glycosylation deficient.

17. The albumin fusion protein of claim 14, wherein said yeast is glycosylation and protease deficient.

18. The albumin fusion protein of claim 1, which is expressed by a mammalian cell.

19. The albumin fusion protein of claim 18, wherein said mammalian cell is a COS, CHO (Chinese Hamster Ovary), or NSO cell.

20. A composition comprising the albumin fusion protein of claim 1 and a pharmaceutically acceptable carrier.

21. A kit comprising the composition of claim 20.